F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: Effect of glycemic control

Flores, Lílliam; Rodela, S; Abian, Joaquín; Clària, Joan; Esmatjes, Enric

doi:10.1016/j.metabol.2004.04.005

Cited by 32 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with previously reported studies, our results confirm that patients with type 1 diabetes have higher levels of oxidative stress than healthy controls matched for age and sex [15,23,27,28].…”

Section: Discussionsupporting

confidence: 93%

“…The intra-individual day-to-day variation of the above-mentioned variables was calculated using a paired samples t test or Wilcoxon's signed rank test, depending on the distribution of the data. Oxidative stress was [15,23], sex [24], age [25] and smoking [17,18,26], all variables that have been reported to be involved in the activation of oxidative stress. For lipid values and blood pressure, we also evaluated the association with urinary excretion of 15 S ð Þ-8-iso-PGF 2α in a univariate model.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis Glucose fluctuations may help predict diabetic complications. We evaluated the relation between glucose variability and oxidative stress in patients with type 1 diabetes. Methods Continuous glucose monitors were inserted subcutaneously in 25 patients. During the measurement, patients collected two 24 h urine samples, while 24 healthy controls collected one 24 h urine sample for determination of 15(S)-8-iso-prostaglandin F 2a PGF 2a ð Þ using HPLC tandem mass spectrometry. Mean of the daily differences (MODD), mean amplitude of glycaemic excursions (MAGE) and continuous overlapping net glycaemic action calculated with n hour time-intervals (CONGA-n) were calculated as markers for glucose variability and correlation with 15 S ð Þ-8-iso-PGF 2α excretion was calculated. Results Median [interquartile range (IQR)] urinary 15 S ð Þ-8-iso-PGF 2α was higher in patients than healthy controls: 161 (140-217) pg/mg creatinine vs 118 (101-146) pg/mg creatinine (p=0.001). Median (IQR) MODD was 3.7 (3.2-5.0) mmol/l, MAGE 7.6 (6.4-9.0) mmol/l and CONGA-1 2.3 (2.1-2.8) mmol/l. Univariate regression did not reveal an association for MODD (r 2 =0.01), MAGE (0.08) or CONGA-1 (0.07) with 15 S ð Þ-8-iso-PGF 2α excretion, nor was an association revealed when corrected for HbA 1c , age, sex and smoking. Spearman correlation coefficients (r) between 15 S ð Þ-8-iso-PGF 2α excretion and MODD, MAGE and CONGA-1 were non-significant: −0.112, −0.381 and −0.177. Conclusions/interpretation We report that there is no relationship between glucose variability and urinary 15 S ð Þ-8-iso-PGF 2α . We also confirm that patients with type 1 diabetes have higher levels of urinary 15 S ð Þ-8-iso-PGF 2α than healthy controls, suggesting that in addition to glucose variability, other factors favouring oxidative stress may exist. We did not see a relation between high glucose variability and elevated levels of oxidative stress in patients with type 1 diabetes.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The method showed potential for the routine determination of urinary iPF 2a -III and 2,3-dinor-iPF 2a -III in clinical samples. Several applications of iPF 2a -III quantitation by LC-MS were reported to evaluate the role of oxidative stress in different diseases (31,32,(55)(56)(57). Recently, F 2 -isoprostane regioisomers and diastereomers formed in vitro were separated and identified by LC-MS (58).…”

mentioning

confidence: 99%

Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS

Yan

Byrd

Ogden

2007

Journal of Lipid Research

103

View full text Add to dashboard Cite

A simple, rapid liquid chromatography-tandem mass spectrometry method was developed to identify and quantitate in human urine the isoprostanes iPF 2a -III, 15-epiiPF 2a -III, iPF 2a -VI, and 8,12-iso-iPF 2a -VI along with the prostaglandin PGF 2a and 2,3-dinor-iPF 2a -III, a metabolite of iPF 2a -III. Assay specificity, linearity, precision, and accuracy met the required criteria for most analytes. The urine sample storage stability and standard solution stability were also tested.The methodology was applied to analyze 24 h urine samples collected from smokers and nonsmokers on controlled diets. The results for iPF 2a -III obtained by our method were significantly correlated with results by an ELISA, although an ?2-fold high bias was observed for the ELISA data. For iPF 2a -III and its metabolite 2,3-dinoriPF 2a -III, smokers had significantly higher concentrations than nonsmokers (513 6 275 vs. 294 6 104 pg/mg creatinine; 3,030 6 1,546 vs. 2,046 6 836 pg/mg creatinine, respectively). The concentration of iPF 2a -VI tended to be higher in smokers than in nonsmokers; however, the increase was not statistically significant in this sample set. Concentrations of the other three isoprostane isomers showed no trends toward differences between smokers and nonsmokers. Among smokers, the daily output of two type VI isoprostanes showed a weak correlation with the amount of tobacco smoke exposure, as determined by urinary excretion of total nicotine equivalents.-Yan, W., G. D. Byrd, and M. W. Ogden. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS.

show abstract

“…Otros efectos identificados son las alteraciones óseas en los niños con bajo peso al nacer [15]. En el aspecto genético, se ha reportado que la existencia de mutaciones a nivel de las proteínas de unión al cobre puede favorecer el desarrollo de diabetes [16], [17] y daño neurológico [18].…”

Section: Cobre (Cu)unclassified

Niveles de metales pesados en muestras biológicas y su importancia en salud

et al. 2015

View full text Add to dashboard Cite

Resumen. En la sociedad del siglo xxi —enfocada hacia el desarrollo socioeconómico—,la continua industrialización, la práctica de la minería y de actividadesproductivas como la agricultura resultan ser opciones atractivas; sin embargo, enel desarrollo de estas actividades, es frecuente el uso y la emisión de algunos químicoshacia el medio ambiente, entre los cuales se encuentran los metales pesados.En el organismo de los seres vivos, hay pequeñas cantidades de algunos metalespesados que pueden intervenir en reacciones bioquímicas, pero otros metales norepresentan utilidad biológica. Por esto, la exposición ocupacional y la exposiciónpasiva a metales pesados presentes en el ambiente o que provienen de la dieta debenser reguladas, ya que cantidades superiores a las consideradas normales puedenocasionar ciertas enfermedades. El control de la exposición a metales pesadosincluye monitorear los niveles presentes en distintas matrices biológicas como lasangre, la orina, la saliva, el cabello y las uñas. Cada una de estas matrices estaráindicada según el tipo de exposición que ha experimentado el individuo; además,ofrecerá algunas ventajas y limitaciones. Es por eso que la presente revisión pretendeinformar sobre los efectos ocasionados en el organismo por niveles excesivosde algunos metales pesados y la utilidad que ofrecen las matrices biológicas en ladeterminación de estos niveles.

show abstract

F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: Effect of glycemic control

Cited by 32 publications

References 18 publications

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes

Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS

Niveles de metales pesados en muestras biológicas y su importancia en salud

Contact Info

Product

Resources

About